Journal of the advanced practitioner in oncology最新文献_第5页

Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube. 又是蜂窝织炎？有胃管的高危实体瘤患儿出现红斑，可能会引发感染。

Journal of the advanced practitioner in oncology Pub Date : 2024-09-01 DOI: 10.6004/jadpro.2024.15.6.2

Kristen L Dalton, Meredith R Johnson

{"title":"Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube.","authors":"Kristen L Dalton, Meredith R Johnson","doi":"10.6004/jadpro.2024.15.6.2","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.6.2","url":null,"abstract":"Background: Proper nutrition is known to hasten healing, reduce treatment-related morbidity, and improve outcomes. Children with high-risk solid tumors often have gastrostomy tubes (GTs) placed for supplemental nutrition during cancer therapy. Gastrostomy tubes, however, are not without risks, and many patients develop erythema concerning for infection at the stoma site. Gastrostomy complications are described in the literature, but knowledge regarding this topic is limited.Methods: In this retrospective descriptive study, the authors reviewed 3 years of clinical data regarding pediatric patients with solid tumors who had GTs at a pediatric medical center. Descriptive statistics were used to describe the incidence of erythema concerning for infection, identify factors most likely to be associated with this complication, and understand how erythema impacts the completion of cancer therapy.Results: In a sample of 58 children with high-risk solid tumors who had GTs placed between 2018 and 2021, 53% developed erythema concerning for infection. More subjects who experienced episodes of GT erythema had neuroblastoma (48%), tubes placed after the start of cancer therapy (74%), and erythema during periods of neutropenia (71%). Only one subject experienced a treatment delay due to GT erythema.Discussion: Despite the rate of GT erythema among study subjects, most completed cancer therapy without delay related to this complication. Additionally, the incidence of stoma site erythema was notably less when tubes were placed prior to the start of cancer therapy. Therefore, the authors recommend GT placement prior to therapy start when possible and further attention be paid to this complication during cancer therapy.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 6","pages":"365-371"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How Do We Achieve Value-Based, Patient-Centered Care? 我们如何实现以价值为基础、以患者为中心的医疗服务？

Journal of the advanced practitioner in oncology Pub Date : 2024-09-01 DOI: 10.6004/jadpro.2024.15.6.1

Beth Faiman

引用次数: 0

Carcinoid Heart Disease. 类癌性心脏病

Journal of the advanced practitioner in oncology Pub Date : 2024-09-01 DOI: 10.6004/jadpro.2024.15.6.3

Nicole Kuhnly, Jessica Shank Coviello, Catherine A Kobza, Devesh A Patel, Jacqueline S Lagoy, Mary-Ann L Cyr

{"title":"Carcinoid Heart Disease.","authors":"Nicole Kuhnly, Jessica Shank Coviello, Catherine A Kobza, Devesh A Patel, Jacqueline S Lagoy, Mary-Ann L Cyr","doi":"10.6004/jadpro.2024.15.6.3","DOIUrl":"10.6004/jadpro.2024.15.6.3","url":null,"abstract":"Carcinoid heart disease (CHD) is a rare cardiac complication that occurs most commonly in patients with advanced neuroendocrine tumors and is a known sequela of carcinoid syndrome. Neuroendocrine tumors most widely associated with CHD include tumors in the small bowel, followed by lung, large bowel, pancreatic, appendiceal, and ovarian neoplasms. Carcinoid syndrome is a paraneoplastic syndrome caused by the release of serotonin and other substances from neuroendocrine tumors. It results in a spectrum of symptoms, including diarrhea, flushing, bronchospasm, and symptoms of congestive heart failure. Without treatment and for patients with advanced heart failure, the prognosis of CHD can be less than a year. Management of CHD is often challenging as patients typically present late, and the disease can progress rapidly. Therefore, optimal management of these patients requires close collaboration among various specialties to quantify disease burden, delay the progression of valvular disease, and determine the most effective surgical and medical management strategies depending on the cardiac manifestations to improve quality of life and reduce mortality. This involves a collaborative team, including cardiology and oncology, and often involves many other disciplines, including hepatobiliary and cardiovascular surgeons, endocrinologists, anesthesiologists, and gastroenterologists.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 6","pages":"378-386"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sutimlimab for Cold Agglutinin Disease. 治疗冷凝集素病的 Sutimlimab。

Journal of the advanced practitioner in oncology Pub Date : 2024-09-01 DOI: 10.6004/jadpro.2024.15.6.4

Mark Reid, Bethany A Fedutes Henderson

{"title":"Sutimlimab for Cold Agglutinin Disease.","authors":"Mark Reid, Bethany A Fedutes Henderson","doi":"10.6004/jadpro.2024.15.6.4","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.6.4","url":null,"abstract":"Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia (AIHA) distinct from warm antibody AIHA. One of the ways it is distinct is that CAD is usually not responsive to corticosteroids compared with warm antibody AIHA. Historically, CAD therapy has been limited to immunotherapy or chemoimmunotherapy with varying responses. Cold agglutinin disease also poses a risk for thrombosis and mortality. For patients, fatigue tends to be a common symptom of CAD. The hallmark of CAD is complement-mediated hemolysis, which makes complement inhibitors a critical therapeutic option for patients. Previously, eculizumab, a C5 inhibitor, had limited therapeutic effect for CAD. More recently, sutimlimab, a C1s inhibitor, was shown in two phase III studies to be an efficacious treatment for CAD, improving hemoglobin, hemolysis, and fatigue. However, there is a paucity of medical literature on CAD and on sutimlimab in particular that is geared toward advanced practice providers (APPs). This article aims to provide APPs with a background in CAD and a focus on sutimlimab, assisting these providers in caring for patients with CAD receiving this therapy.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 6","pages":"389-395"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence: How Is it Relevant to Advanced Practitioners? 人工智能：它与高级从业人员有何关系？

Journal of the advanced practitioner in oncology Pub Date : 2024-07-01 DOI: 10.6004/jadpro.2024.15.5.1

Beth Faiman

引用次数: 0

How Can Oncology Nurses and Advanced Practice Providers Reduce the Burden of Chemotherapy-Induced Febrile Neutropenia in the US? 在美国，肿瘤护士和高级执业医生如何减轻化疗引起的发热性中性粒细胞减少症的负担？

Journal of the advanced practitioner in oncology Pub Date : 2024-05-22 DOI: 10.6004/jadpro.2024.15.8.5

Kristi Kay Orbaugh, Sandra Cuellar, Lisa Kennedy Sheldon

{"title":"How Can Oncology Nurses and Advanced Practice Providers Reduce the Burden of Chemotherapy-Induced Febrile Neutropenia in the US?","authors":"Kristi Kay Orbaugh, Sandra Cuellar, Lisa Kennedy Sheldon","doi":"10.6004/jadpro.2024.15.8.5","DOIUrl":"10.6004/jadpro.2024.15.8.5","url":null,"abstract":"Background: Neutropenia and febrile neutropenia (FN) are serious complications of myelosuppressive chemotherapy and present a considerable burden to patients with cancer. Febrile neutropenia is associated with increased risks of infection and hospitalization, a particular concern during the coronavirus disease 2019 (COVID-19) pandemic. Oncology nurses and advanced practice providers (APPs; including nurse practitioners, physician assistants, advanced practice nurses, and pharmacists) play a vital role in the management of patients with cancer and the prevention of infections.Objectives: The objectives of this article are to summarize the burden of chemotherapy-related neutropenia and FN in patients with cancer in the US and to evaluate the role of oncology nurses and APPs in preventing and managing FN.Methods: This article provides a narrative review of US studies reporting on the burden of FN, FN during COVID-19, adherence to guidelines for the use of prophylactic granulocyte colony-stimulating factors (G-CSFs), the involvement of oncology nurses in FN prevention, management, and patient quality of life, and inappropriate and/or incomplete G-CSF treatment.Findings: Despite advances in supportive care for patients with cancer receiving myelosuppressive chemotherapy, neutropenia and FN present a considerable burden to patients, particularly during the COVID-19 pandemic. Oncology nurses and APPs play a vital role in the appropriate and timely delivery of supportive care, which can improve patient outcomes and minimize treatment costs.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Pelvic Floor Rehabilitation on Low Anterior Resection Syndrome After Colorectal Cancer Treatment. 盆底康复对结直肠癌治疗后下前切除术综合征的影响。

Journal of the advanced practitioner in oncology Pub Date : 2024-05-22 DOI: 10.6004/jadpro.2024.15.8.4

Shelby Jones, Alison Edie, Emily Troop, Joshua S Hill, Julie A Thompson

{"title":"The Effect of Pelvic Floor Rehabilitation on Low Anterior Resection Syndrome After Colorectal Cancer Treatment.","authors":"Shelby Jones, Alison Edie, Emily Troop, Joshua S Hill, Julie A Thompson","doi":"10.6004/jadpro.2024.15.8.4","DOIUrl":"10.6004/jadpro.2024.15.8.4","url":null,"abstract":"Purpose: Low anterior resection (LAR) is the preferred surgical treatment of rectosigmoid or rectal cancers. However, it is often associated with bowel dysfunction, which is termed low anterior resection syndrome (LARS). Daily bowel dysfunction symptoms have a detrimental effect on quality of life (QOL). Pelvic floor rehabilitation (PFR) can improve pelvic floor function and QOL among patients with LARS. This quality improvement (QI) project seeks to assess the prevalence of LARS and develop and incorporate PFR for the treatment and prevention of LARS.Methods: A convenience sample of 20 patients met project inclusion. Thirteen patients participated. Individuals were categorized by diagnostic risk: low risk, high risk, and established. The intervention included 1-hour PFR sessions with the physical therapist (PT) and 5 minutes of daily self-led pelvic floor muscle exercises. Outcomes questionnaires included the LARS Score and Fecal Incontinence Quality of Life (FIQOL) Scale. Data were collected both pre- and post-colorectal cancer treatment.Results: The overall prevalence of LARS was 76.9%, which was significantly higher than the retrospective cohort comparison rate of 21.8% (p < .001). The prevalence of major LARS was 89%, 83%, and 50% at the initial, second, and third sessions, respectively, representing a 44% relative decrease. Embarrassment was significantly affected among individuals with major LARS, although ongoing PFR facilitated improvement.Conclusion: PFR is a valuable adjunct therapy for LARS, with continued sessions decreasing the overall prevalence among the cohort. Major LARS negatively impacts QOL measures early on in treatment but improves with continued PFR.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib. 骨髓纤维化治疗的进展：新的Janus激酶抑制剂超越鲁索利替尼。

Journal of the advanced practitioner in oncology Pub Date : 2024-05-22 DOI: 10.6004/jadpro.2024.15.8.6

Justin Arnall, Lindsey Lyle, Donald C Moore

{"title":"Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib.","authors":"Justin Arnall, Lindsey Lyle, Donald C Moore","doi":"10.6004/jadpro.2024.15.8.6","DOIUrl":"10.6004/jadpro.2024.15.8.6","url":null,"abstract":"Myelofibrosis is a myeloproliferative neoplasm characterized by the buildup of fibrous scar tissue in the bone marrow occurring secondary to the secretion of inflammatory cytokines, leading to cytopenias, dysfunctional hematopoiesis, and constitutional symptoms. One of the pathologic mechanisms that underlies myelofibrosis is aberrant activation of the Janus kinase (JAK)-STAT pathway. Targeting the JAK-STAT pathway via JAK inhibition can lead to significant improvements in spleen volume reduction and symptom improvement in intermediate- and high-risk myelofibrosis. The first JAK inhibitor approved by the US Food & Drug Administration was ruxolitinib in 2011. Recently, there have been additional JAK inhibitors approved for myelofibrosis, including fedratinib, pacritinib, and momelotinib. The emergence of these new therapies offers additional treatment options for patients with myelofibrosis. This article reviews the pharmacology, efficacy, safety, dosing, administration, and implications for advanced practitioners of newer JAK inhibitors (fedratinib, pacritinib, and momelotinib) in the treatment of myelofibrosis.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Growth Factor in the Setting of CAR T-Cell Therapy: To Use or Not to Use. CAR T 细胞疗法中的生长因子：用还是不用？

Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.3

Cindy L Cao, Ashley Martinez, Joyce Dains

{"title":"Growth Factor in the Setting of CAR T-Cell Therapy: To Use or Not to Use.","authors":"Cindy L Cao, Ashley Martinez, Joyce Dains","doi":"10.6004/jadpro.2024.15.4.3","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.3","url":null,"abstract":"Patients undergoing chimeric antigen receptor (CAR) T-cell therapy may experience side effects including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), neutropenia, and infection. Growth factor has historically been used to treat neutropenia; however, its role in CAR T-cell therapy is not well explained. Existing data on the safety and efficacy of growth factor are conflicting. The purpose of this integrative review was to explore the safety and efficacy of growth factor in adult patients with hematologic malignancies undergoing CAR T-cell therapy. A literature review was conducted using PubMed, Cumulative Index to Nursing & Allied Health (CINAHL), and Scopus databases. A total of 2,635 articles were retrieved. Four studies were included that looked at the use of growth factor in the CAR T-cell setting. Safety outcomes evaluated included CRS, ICANS, neutropenic fever and/or infection, and neutropenia duration. Efficacy outcomes evaluated included CAR T-cell expansion and treatment response. The literature suggests that growth factor may not increase CRS prevalence, but may lead to an increased grade of CRS, namely grade 2. Growth factor administration does not have any association with ICANS toxicity, CAR T-cell expansion, or treatment response. Its use may not necessarily lead to decreased infection rates but may shorten the duration of neutropenia. Practice implications for providers working with this unique patient population include using growth factor early in the course of CAR T-cell therapy as treatment to shorten the duration of neutropenia rather than infection prophylaxis.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"253-264"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Music Therapy as an Adjunctive Treatment in Pediatric Cancer Patients Receiving Traditional Therapies: A Systematic Review. 音乐疗法对接受传统疗法的儿童癌症患者的辅助治疗效果：系统回顾

Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.4

Debra M Cole, Kaitlin Beane, Madeleine Engel, Madison Shaffer, Sarah Tartabini

{"title":"The Effect of Music Therapy as an Adjunctive Treatment in Pediatric Cancer Patients Receiving Traditional Therapies: A Systematic Review.","authors":"Debra M Cole, Kaitlin Beane, Madeleine Engel, Madison Shaffer, Sarah Tartabini","doi":"10.6004/jadpro.2024.15.4.4","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.4","url":null,"abstract":"Aim: This study aimed to analyze articles that discussed the effect of music as adjunctive therapy to traditional treatments of pediatric cancer patients compared to a control of no music therapy.Background: Cancer is a leading cause of death in children, with over 400,000 children diagnosed annually. During standard oncologic treatments, children often experience psychological and physical adverse effects. The use of music therapy can provide numerous supportive benefits to pediatric patients as adjunctive treatment in reducing psychological and physical burdens.Design: This was a systematic review of English-language articles from PubMed.Methods: Nine outcome articles were utilized in this systematic review, including quantitative and qualitative reviews of case studies, interviews, historical accounts, randomized control trials, and other systematic reviews.Results: The study found increased quality of life (QOL) involving dimensions of mood, cognition, relaxation, self-esteem, vitality, and a sense of community involving interpersonal relationships. The implementation of music therapy in pediatric oncology patients decreased stress/distress and pain. Qualitative data suggests QOL dimensions of localization and control of feelings, sense of community involving social roles and ecological health, stress, distress, and pain, improved in pediatric oncology patients receiving music therapy.Conclusion: The literature supports music therapy as a complementary treatment during traditional therapies to help decrease stress and pain in children and improve quality of life and sense of community. Therefore, music therapy as an adjunctive therapy should be implemented into standard practice.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"265-276"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0